Spring 2021 1 - Apex Labs
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Title
Spring
20211Acknowledgement of Confidentiality
This corporate presentation (“Presentation”) is confidential and contains proprietary non-public information regarding Apex Labs Ltd. (the “Company”, “we”, “us” or “our”).
This Presentation is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company. The information contained herein has been prepared for the
purpose of providing interested parties with general information to assist them in their evaluation of the Company. Under no circumstances may the contents of this Presentation be reproduced, in whole or in part,
in any form or forwarded or further redistributed to any other person. Any forwarding, distribution or reproduction of this document in whole or in part is unauthorized. By accepting and reviewing this document,
you acknowledge and agree (i) to maintain the confidentiality of this document and the information contained herein, and (ii) to protect such information in the same manner you protect your own confidential
information, which shall be at least a reasonable standard of care. The Company has not authorized anyone to provide prospective purchasers with additional or different information. In this Presentation all amounts
are in Canadian dollars unless stated otherwise.
This Presentation constitutes “forward-looking statements,” within the meaning of applicable Canadian securities laws. Forward-looking statements are neither historical facts nor assurances of future performance.
Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future
conditions. These forward-looking statements appear in a number of places throughout this Presentation and can be identified by use of words, such as “anticipates”, or “believes,” “budget,” “estimates,” “expects,”
or “is expected,” “forecasts,” “intends,” “plans,” “scheduled,” or variations of such words and phrases or state that certain actions, events or results “may,” “might,” “will,” “would,” “could”, “should,” “continue,” or be
taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals
or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, these forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements.
Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. Despite a
careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-
looking statements is to provide the reader with a description of management’s expectations regarding our anticipated future performance and may not be appropriate for other purposes. Furthermore, unless
otherwise stated, the forward-looking statements contained in this Presentation are made as of the date of this Presentation and we do not undertake any obligation to update publicly or to revise any of the included
forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable legislation or regulation. The forward-looking statements contained in this document
are expressly qualified by this cautionary statement.
This Presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys
and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to the limits on the
availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources
referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.
2Forward Looking Statements
This presentation contains forward-looking statements. These forward-looking statements are not based on
historical facts but rather on Company management expectations regarding future growth, results of operations,
performance, future capital and other expenditures (including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Statements in this presentation about future plans
and intentions, results, level of activity, performance, goals or achievements or other future events constitute forward
looking statements. Wherever possible, words such as “anticipate”, “believe”, “expect”, “may”, “could”, “will”, “forecast”,
“potential”, “intend”, “estimate”, “should”, “plan”, “predict” or the negative or other variations of statements reflect
managements’ current beliefs and assumptions and are based on information currently available to the Company
management. Certain risk factors may cause actual results, level of activity, performance or achievements to differ
materially from those implied by forward looking statements. These factors should be considered carefully and
prospective investors should not place undue reliance on the forward looking statements. Although the forward-looking
statements contained in this presentation are based upon what the Company management believes to be reasonable
assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements.
These forward-looking statements are made as of the date of this presentation, and the Company assumes no
obligation to update or revise them to reflect new events or circumstances.
3Who
Title We Are
Over 1 billion people suffer
fromsome form of compromised
mental health. 1
APEX’s objective is to be a leading pharmaceutical company bringing
psychedelic drug product to market for patients suffering from post-
traumatic disoder (PTSD), depression, addiction and other related mental
health conditions. APEX’s Canadian clinical development program is focused
on veterans and first responders - groups that are most affected by these
disorders. The Company’s lead clinical candidate is a synthetic psilocin for
the treatment of PTSD.
4Corporate Statements
Mission Vision Strategy
To execute on our mission, APEX is Through clinical trials and other research, APEX has fast-tracked
undertaking one of the first Canadian phase APEX aims to showcase the benefits of commercialization through agreements
II clinical trials using synthetic psilocin extracted botanically-sourced tryptamines, with Innovative Phytotechnologies Inc.
(the active metabolite of psilocybin). Upon beta-carbolines and other compounds, and (Innovate), a late-stage applicant for
successful completion of a phase II clinical also of single-molecule synthetic psilocin. a Food and Drug Regulations Part J
trial, APEX plans to move to phase III We will conduct side-by-side clinical trials dealer’s licence (DL) and Dalton Pharma
clinical trials. demonstrating the high level of efficacy of Services (Dalton), a licensed dealer.
our extracts and pure psilocin products. Under agreement with APEX, Innovate
will cultivate psilocybin-producing fungi
and extract compounds from the fungi,
while Dalton will manufacture psilocin
drug products.
5Canada’s Health Landscape 2
Leading cause of deaths nationwide
Estimated annual
economic burden of
9 th are attributed to suicide with an
$51B mental illness in Canada
average of 11 per day
20%
Number of Canadians
Number of Canadians who suffer who will be affected by
from addiction in any given year 50% mental health issues by
4 th the age of 40
76%
Canada’s worldwide
rank per capita in 9%
anti-depressant Of Canadians suffer
drug usage Of Canadians have reported Of PTSD patients 8% from PTSD at least
experiencing a traumatic event once in their lifespan
are not receptive to
reshaping their mental health current traditional
treatments 6Global Problems & Solutions
APEX is The Answer
APEX seeks to demonstrate safety and efficacy of
pure psilocin, and botanically sourced tryptamines
and other compounds, in medicines for a continuum of
mental illnesses and unmet medical needs. Naturally
occurring psychedelics such as psilocybin and psilocin
(Psilocybe cubensis and other species of fungi), mescaline MHD 450 million PTSD 351 million
(Lophophora williamsi and other species of cacti), salvinorin
A (Salvia divinorum) and ibogaine (Tabernanthe iboga) have
been used traditionally for centuries to treat a wide array of
maladies and stimulate spiritual growth.
APEX plans to develop drug products from both synthetic
and botanically sourced compounds, differentiating
APEX from the pack by diversifying APEX’s options for
commercialization of drug products.
Opioid 27 million Depression 254 million
7Global Problems 3
1 MHD 450 million 2 PTSD 351 million
Over 450 million people suffer from Mental Health Disorders An estimated 351 million people are living with PTSD in the
on a global scale, with an estimated $51b of annual economic world today. 8% of Canadians will suffer from PTSD at least
impact within Canada alone. 50% of Canadians will be affected once in their lives.
by mental health issues by the age of 40, while 76% of all
Canadians having reported experiencing a traumatic event 9% of PTSD patients are not receptive to current traditional
reshaping their mental health. treatments.
3 Opioid 27 million 4 Depression 254 million
Today it’s estimated over 27 million people have opioid An estimated 254 million people are battling depression globally
addiction problems globally. 20% of Canadians suffer today. Canada is ranked 4th in anti-depressant drug usage per
from addiction in any given year. capital with suicide as a result of depression being the leading
cause of deaths nationwide.
8Management
Tyler Powell Mirza Rahimani CPA, CA Dr. Orion Lekos
Chief Executive Officer CEO Chief Financial Officer CFO Chief Scientific Officer CSO
Mr. Powell is an entrepreneur with 15 years Over twelve years of experience working Our Chief Science Officer, Dr. Lekos, has
of experience in the financial sector. He with early and development stage participated and led global clinical trials on
has led the going-public transactions for companies, primarily in the context of going epilepsy, glioblastoma, nausea and vomiting
multiple companies on the Canadian, US and or being public. Mr. Rahimani has served as induced from chemotherapy. Dr. Lekos has
German exchanges, raising tens of millions a director and officer of TSX-V listed public facilitated the development, design and build
in corporate financings through several companies and been involved in reverse of numerous extractions and formulations
channels along the way. He is the Chief takeover, initial public offering, and other for Tilray - a large Canadian cannabis
Executive Officer and founder of the go- public company related transactions. He is a processing company with operations in
public vehicle called Murdo Acquisitions Corp. chartered professional accountant, and has Australia, New Zealand, Germany, Portugal
earned a bachelor of commerce from the and Latin America.
University of British Columbia.
9Management Cont.
Dr. Peter Tomlinson Arron Victory Alex Winstead
Chief Marketing Officer CMO Chief Strategy Officer CSO Chief Cultivation Officer CCO
Dr. Tomlinson is a highly sought out Mr. Victory has provided companies Alex Winstead is a top North American
consultant and a prominent industry leadership teams and advisory boards mycologist and mushroom cultivator with
leader, who specializes in supporting guidance on issues ranging from patient over 16 years experience in the gourmet and
pharmaceutical and biotechnology focused care to long term operational medicinal mushroom industry. His company,
companies in the process of transitioning planning with years of legacy experience Cascadia Mushrooms LLC of Bellingham,
new products into early clinical trials and in both the cannabis industry and the Washington, is where Alex and his team grow
commercialization. He has partnered with psychedelics space. Arron maintains a thousands of pounds of certified organic
leading companies across the globe, such position as an ambassador for Wounded mushrooms every week. Their efforts supply
as such as Tilray Pharmaceuticals, Aegera Warriors Canada and an advisory position a variety of markets with raw products
Therapeutics, Purgenesis Technologies, with the Chronic Pain Centre of Excellence for medicinal extraction and supplement
Ultragenyx Pharmaceutical, Sharp and Heroic Hearts Project. formulation across the U.S. as well as fresh
Corporation, Taro Pharmaceuticals and gourmet mushrooms to local and wholesale
Supratek Pharma. outlets throughout the region.
10Partners and Associates
Dalton Pharma Services Innovate Phytotechnologies Inc. The Newly Institute Inc.
Toronto based Dalton has successfully Innovate operates a 10,000 square foot state- Newly will host APEX’s phase II trials with
formulated a 90-gram test batch of of-the-art laboratory with infrastructure for their Chief Medical Officer Dr. Robert
synthetic Psilocin for APEX which is analytical testing, formulation, validation, Tanguay acting as Principal Investigator (PI)
currently in stability and stress tests with genomic and metabolic fingerprinting, tissue as well as working hand-in-hand with APEX
a certificate of analysis expect by end of culture, genetic development, and small batch and Dr. Paul Smith to help veterans and
Q2 of 2021 with a batch manufactured manufacturing. Innovate expects to receive its first responders from its multiple locations
to good manufacturing practices (GMP) dealer’s license by end of Q2 2021 to authorize nationwide. Newly’s focus on ketamine
standards and suitable for use as an active cultivation of psilocybin-producing fungi, and psychedelics brings expertise and
pharmaceutical ingredient (API) of 100+ extraction from fruiting bodies and formulation infrastructure suitable for psychedelic-
grams to be ready during Q3 of 2021, and of extracts. assisted psychotherapy required for
suitable for use in manufacturing services APEX’s clinical trials.
to the pharmaceutical and biotechnology
industries.
11Advisors
Dr. David Wood Intellectual Property and Regulatory attorney and patent agent w/ BLG
Dr. Emmanouil Rampakakis Clinical trial protocols specialist
Dr. Robert Tanguay Principal Investigator for clinical trials
Dr. Paul Smith Patient recruitment for Veteran focused clinical trials
Dr. Jacek Usakiewicz Innovate Phytotechnologies Inc. – Drug design and assay development
Dr. Lukman Sarker Innovate Phytotechnologies Inc. – Genetics and sequencing
Denis Silva Securities attorney with DLA Piper
John Karroll Health Canada licensing consultant
Bob Cross Capital Markets and Innovate Joint Venture
Susan Chappelle Operations
Arthur Kwan Fund Manager and The Newly Institute Joint Venture Partner
123 Phase Approach
Research 2 Clinical Trial Clinical Trial
1 & Development Planning
3 Execution
Dr. Lekos oversees research and Dr. Tomlinson oversees regulatory Dr. Lekos will be added to Innovate’s
development (R&D) alongside Dr. efforts and will manage the clinical trial dealers license (once issued) as an
Usakiewicz and Dr. Sarker with the application (CTA) for all clinical trials A/QPIC. His expertise in conjunction
Innovate team to head research on with help from the clinical research with with Dr. Tomlinson’s GMP expertise
genetics, extraction and formulation of organization (CRO) JSS Medical will allow APEX to sell develop, protect
botanical psilocybin products for clinical Research based out of Montreal. and commercialize drug products
trials. Dr. Lekos will head further R&D Newly will support the clinical trials manufactured constently with GMP
projects using controlled substances as a site and will assist with patient standards. At least two different drug
to be added as A/QPIC* to Innovate’s recruitment. products are planned for clinical trials -
dealer’s license once the licence issues. one with psilocin as an API and another
with a botanical extract including
* A qualified person in charge (“QPIC”) is responsible for supervising all activities with controlled substances at a licensed dealer’s site. psilocybin, other tryptamines and beta
A licensed dealer may only deal with controlled substances at their site if the QPIC or an alternative QPIC (“A/QPIC”) is present at the site. carbolines as an API.
13Critical Path
APEX, working with Innomar Strategies has communicated with Health Canada
1 Pre-CTA* Meeting and exchanged drafts of materials for review during a pre-clinical trial meeting.
With Health Canada’s approval of the CTA, APEX will be on track to launch its
2 CTA Approval clinical trials.
Once the CTA is approved, APEX will file an application for a subsection 56(1)
3 Clinical Trials Exemption exemption to use controlled substances in the clinical trials.
Access to Innovate lab allows Innovate to cultivate, extract, formulate, import and
4 Dealers Licence export controlled substances for the benefit of APEX’s clinical trials.
Innovate’s DL site is built to Compliance with Level 6 of the Security Directive**,
5 Security allowing ample storage of controlled substances.
* clinical trial application
** Directive on Physical Security Requirements for Controlled Substances and Drugs Containing Cannabis
14Path to Revenue
1 2 3 4
Licencing Product Clinical Approved
Access to Innovate’s DL Development Trials Drug Products
and a subsection 56(1) Dalton is manufacturing a psilocin Collection of data and APEX, potentially
exemption respectively drug product. Innovate is working medical analyses of Veterans through a joint venture
allow APEX to direct with APEX to extract tryptamines and first responders suffering or post-acquisition by a
work with controlled and other compounds from fruiting from PTSD, traumatic brain pharmaceutical company,
substances and to bodies and manufacture a drug injuries and chronic pain for plans to bring a psilocin drug
undertake clinical trials. product from the extract. APEX both the psilocin drug product product, a botanical extract
will assess patentability and where and the botanical extraction drug product, or both, through
appropriate file patent applications drug product. the regulatory approval
protecting the products and also process to market.
manufacturing methods.
15Patient Recruitment
APEX plans to work with Newly to further identify how veterans
and first responders can benefit from psychedelic supported
psychotherapy from an evidence-based perspective. With the help
of Dr. Tanguay, Dr. Smith and Dr. Wood, the APEX and Newly Teams
will sponsor treatment for Canadian veterans suffering from chronic
conditions, who seek relief with comprehensive Blue Cross coverage.
We are committed to making a difference.
APEX’s veteran focused research team will be studying on PTSD,
traumatic brain injuries and chronic pain in the Canadian veteran
community. We believe in a whole-person approach to recovery for
veterans and first responders who suffer from chronic service-related
conditions
16Clinical Trials
The New Gold Standard
The APEX team has developed a protocol for a veteran and first
responder focused Phase II clinical trials focused on PTSD and
chronic pain in winter 2020 with a start date pending Health Canada’s
comments under a pre-CTA review. APEX has sourced GMP API and
drug product to facilitate our first trials in 2021. Under the review of
Dr. Lekos, Dr. Tomlinson, Dr. Rampakakis, Dr. Tanguay and Dr. Smith,
APEX is set to define the new gold standard in Canadian psychedelic
clinical trials.
APEX is currently in dialogue with Health Canada to define the scope
and reference materials for a pre-CTA meeting.
17Intellectual Property
Genetic Registration & Rights
APEX intellectual property development plan prioritizes patent protection of
compositions, formulations and target indications for the formulations. We combine
these aspects together in order to bolster our patent claims, particularly in
formulations prepared from extracts of fungal biomass.
There is an incredible opportunity for developing and securing intellectual property
rights in the psilocybin and psychedelic space. APEX is working hand-in-hand with
our intellectual property counsel at Cooley LLP and BLG Canada LLP, identifying
the assets that can be protected and effectively captured to capitalize on.
18Market Comparisons
1 Mind Medicine $922.95 M 4 Compass Pathways $1.49 B
18-MC therapy for treatment of opioid use disorder, 18-MC is Psilocybin therapy for treatment resistant depression, In-clinic
derived from Ibogaine. supervision required, based in London, UK.
2 Field Trip Health $218.42 M 5 Numinus Wellness $166.61 M
Field Trip blends legal psychedelic-enhanced therapy, Numinus is a mental health company creating an ecosystem of
mindfulness, and self-care with a series of sessions with trained health solutions to research, develop, and deliver safe, evidence
psychotherapists in a spa-like environment. based, accessible psychedelic-assisted psychotherapy.
3 Mydecine Innovations $55.34 M 6 Cybin Pharmaceuticals $215.81 M
A publicly traded life sciences parent company dedicated to Cybin is a leading biotechnology company focused on
the development and production of adaptive pathway medicine progressing psychedelic therapeutics by utilizing proprietary
solutions. drug discovery platforms.
* MARKET VALUATIONS AS OF APRIL 20TH, 2021.. PRICES IN CAD. 19Financing Opportunity
Proceeds
7,617,000 shares at $0.10 Secured Richmond, BC lab location, synthesized
1 $0.10 Friends + Family Round
Closed
$761,700
with full warrant at $0.20 psilocin product and clinical trial protocols (minus fees)
8,000,000 shares Completes product manufacturing, Innovate lab
2 $0.25 Series A
Open
$2,000,000
available at $0.25 investment and partnership and begins clinical trial cycle
(minus fees)
Completes Phase II clinical trials, large ownership of
18,000,000 shares available $9,000,000
3 $0.50 RTO Public Listing Innovate partnership, pubco marketing and working
(minus fees)
with half warrant at $0.75
capital funded and secured
I/O: 43,377,000
Murdo Acquisitions Corp
Share Structure has 1,760,000 shares I/O
Three rounds of financing 8,000,000 fullly financed
Issued & Outstanding (I/O) 34,000,000 shares builders shares $11,761,700
including distribution
+ warrants
* Numbers are not final and may be subject to change.
20Private Project Cost
Unallocated
Working Capital
12 Month Runway 11%
Phase II
clinical trial
The Company is currently in the process of 13%
seeking a $11.0 million financing concurrent
with a planned listing through a share
exchange (“RTO”) on the CSE followed by Innovate
a move to the tier one NEO exchange. The Reserved for
Strategic Investment Lab JV
primary use of funds will be the completion 32% 9%
of the Phase II clinical trial, the investment
in Innovate, strategic investments in key
Inventory
partners, and the working capital necessary
3%
for the manufacture of the APIs.
General &
Administrative Marketing &
14% Investor Relations
Financing & 9%
Commissions
9%
21Appendix — Partners & Associates
Innomar Strategies The Newly Institute
Pre-CTA Health Canada Canadian Wellness Centers working
specialist handling APEX’s directly with APEX’s formulations and
literature dive for clinical trials. product delivery.
Mykology
Extraction,
formulation and
DLA Piper genetics specialist
World largest and leading legal
firm managing the go public
route for APEX. BLG Law
Canada’s largest law
AlthoTech firm handling APEX’s
TriChome Canadian IP.
GMP certification Health Canada licensing
expert consulting JSS Medical
specialist consulting firm. Research
outfit. SGS Canada
The world’s Clinical Research
Cascadia Mushrooms Dalton Pharma leading inspection, Organization
Pacific North-West leading Pharmaceutical cGMP verification, testing (CRO) handling
organic cultivation. Manufacturing Lab. and certification clinical trials and
company. protocols.
22Appendix — Footnotes
Global Stats
www.ncbi.nlm.nih.gov/pmc/articles/PMC6394282
www.who.int/news-room/fact-sheets/detail/depression
www.who.int/substance_abuse/information-sheet/en
www.who.int/whr/2001/media_centre/press_release/en
Canadian Stats
www.cpa.ca/sections/traumaticstress/simplefacts
www.health.gov.on.ca/en/public/publications/mental/depression.aspx https://www.addictioncenter.com/addiction/addiction-in-canada
www.canada.ca/en/public-health/services/publications/diseases-conditions/mood-anxiety-disorders-canada
23Contact
Thank You
Name Apex Labs Ltd.
Address Suite 400 - 110 Cambie Street, Vancouver, BC V6B 2M8
Aquired 13351 Commerce Parkway, Richmond, BC V6V 3A1
Phone (778) 994-8050
Email tyler@apexlabsltd.com
24You can also read
